Gender, genetics, and analgesia: understanding the differences in response to pain relief

Senthil Packiasabapathy
Senthilkumar Sadhasivam
Department of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA

Abstract: Genetic variations and gender contribute significantly to the large interpatient variations in opioid-related serious adverse effects and differences in pain relief with other analgesics. Opioids are the most commonly used analgesics to relieve moderate-to-severe postoperative pain. Narrow therapeutic index and unexplained large interpatient variations in opioid-related serious adverse effects and analgesia negatively affect optimal perioperative outcomes. In surgical, experimental, chronic, and neuropathic pain models, females have been reported to have more pain than males. This review focuses on literature evidence of differences in pain relief due to multiple genetic variations and gender of the patient.

Keywords: pain, analgesia, pain genomics, pharmacogenomics, pharmacokinetics, pharmacodynamics

Introduction
Individual variation in pain perception and response to analgesics has been a subject of interest for quite some time now. Genetic factors and sex of the patient are associated with differences in analgesia. For instance, the MC1R gene, which is associated with fair skin and red hair, has been found to play a role in sexual dimorphism of kappa-opioid analgesia. Red-haired women, with two variants of the MC1R allele, showed significantly greater analgesia in response to pentazocine, compared to red-haired men. This is an example of the role played by chromosomal sex in dissimilar responses to analgesic therapy, secondary to a specific genotype. There have been case reports of life-threatening respiratory depression in response to tramadol, codeine, and so on, in extensive metabolizers (EMs) of the prodrugs to their respective active forms. There are a number of other factors such as age, body composition, hormonal milieu, comorbid conditions, co-existing pharmacotherapy, past pain experiences, and environmental and psychosocial factors that play a role in the individual variation in the experience of pain and analgesia. Curiosity in this individual variation began ever since the period of Pythagoras, who noticed that some experienced fatal reactions on ingesting fava beans and others did not. Today, in an era of epigenetic therapies, understanding the genetic and gender differences in drug metabolism and drug response holds extreme significance and it has been facilitated by the successful completion of the human genome project in 2003.

This review aims to shed light on the gender differences and pharmacogenetics relevant to pain management. Pain is a subjective experience, which includes physical as well as emotional components, and is difficult to measure objectively. Each person
is unique in perception and response to pain and so is each individual’s response to analgesic therapy. The WHO pain ladder, which is a simple yet effective algorithm to manage pain, is nonetheless, an over-generalized management guideline when individual differences are considered. Understanding these differences is the first step toward individualized medicine or tailoring therapy to each individual, or in other words, a step toward “ideal analgesic therapy”.

Gender differences in pain perception
In order to understand the gender difference in response to pain relief, understanding the gender difference in pain perception is the first essential step. It has been now understood that this difference is due to a multitude of other factors than just the chromosomal sex. Hence, it is more appropriate to address it as “the gender difference”, as it encompasses the psychological and social aspects of sex as well. Phenotypic expression of various alleles has more relevance in individual differences in pain perception and analgesic response, rather than just the presence of a distinct genotype, and this expression, in turn, is influenced by a number of other internal and environmental factors.

There are a number of studies that examine the gender differences in pain perception. Though the results are mixed, a majority of them point in the direction of increased sensitivity to pain in females.6 Females are at an increased risk of many chronic pain conditions compared to males. The population prevalence of several pain conditions such as migraine, tension headache, irritable bowel syndrome, and fibromyalgia is higher in females.6–9

Females also show a higher incidence of acute postoperative pain.6 Females are also reported to have an increased sensitivity in a number of experimental pain models. This includes pain induced by electrical, thermal, mechanical, chemical stimuli, or more advanced, clinically relevant pain models such as the temporal summation of pain and conditioned pain modulation (CPM). Temporal summation measures pain facilitation in response to repeated stimuli over a period of time. CPM measures a decrease in pain perception in response to a “conditioning pain stimulus”. It is based on “pain inhibits pain” model and is used to assess endogenous antinociception. Responses are measured in terms of pain intensity scales such as the visual analog scale, self-reported unpleasantness rating, and in terms of threshold and tolerance. Threshold measures the time or intensity of stimulus at which the subject first reports pain perception. Tolerance is the maximum amount of pain stimulus the subject is able to withstand. In general, females display a lower pain threshold and tolerance to painful stimuli compared to males. Women show a greater temporal summation of pain (pain facilitation), whereas men show better pain modulation (pain inhibition).6–9 Pain modulation through diffuse noxious inhibitory control (DNIC) has been found more efficient in men than in women.10 In a recent review by Hermans et al, nine of the 15 studies that compared CPM between males and females did not find any difference between the genders. The remaining six studies found that males demonstrated better CPM compared to females.11 Though evidence of gender difference in CPM is not compelling, those studies that show a difference consistently point toward greater CPM in males.

Causes of gender differences in pain perception
Sex hormones and neural correlates
Sex hormones have been known to play a significant role in gender difference in pain perception and analgesia.12 Testosterone has been found to decrease pain sensitivity, and a low testosterone state has been demonstrated in many chronic pain conditions,13 but the effects of estrogen and progesterone on pain are more complicated, with both pro- and antinociceptive properties.14,15 Use of exogenous sex hormones has also been related to an increased risk of chronic pain conditions.16 Considering the role of sex hormones in nociception, intragroup variation in pain perception in females and variations in the same individual at various stages of sexual development and cyclical variation with the menstrual cycle hold clinical significance, though the literature evidence is inconsistent.17–20 For instance, many studies suggested that females in postovulatory luteal phase show increased pain sensitivity compared to follicular phase.21 Pain symptoms in chronic pain conditions seem to be most severe around menstruation, associated with the falling levels of estrogen.17,22 Other studies have shown an association between high levels of female reproductive hormones and pain conditions.16,22 To add to this controversy, there is a growing body of recent literature, suggesting a lack of variability in pain response across the menstrual cycle.22,23 More studies are required to gain further insight.

Age of the individual plays an important role in pain sensitivity and analgesic response due to variation in sex hormone levels and differences in body composition and metabolic ability. Many chronic pain conditions show no difference in prevalence, between genders, and before puberty.12 Females show an increased prevalence of these conditions around puberty.24 Gender difference in
cortical pain processing has also been demonstrated. Neuroimaging has demonstrated reduced pain-related activation of CNS antinociceptive pathways in females with low testosterone levels. Animal studies also show a sexual dimorphism in the anatomy and function of the CNS pain modulatory system. Midbrain periaqueductal gray (PAG) matter and its descending projections to the rostral ventromedial medulla (RVM) and spinal cord form an important descending antinociceptive pathway. Pain stimulates PAG, resulting in the release of endogenous opioids. Studies in rats showed no qualitative sex difference in the PAG–RVM system, but quantitatively, female rats had a greater number of neurons compared to the males. On the contrary, functional studies have shown significantly lower activation of PAG–RVM neurons in response to persistent inflammatory pain in female rats compared to male rats. Despite this difference, both male and female rats exhibited similar hyperalgesia after chemically induced inflammatory pain. This suggests the existence of alternative, sex-specific pain-modulating pathways.

Sexual dimorphism has also been observed in mu-opioid receptors (MOR). Males have higher levels of MOR expression and better opioid binding in the rostrocaudal axis of PAG. This may have an association with increased androgen receptor (AR) expression in PAG neurons. Estradiol, in contrast, has been known to cause MOR internalization and to attenuate neuronal hyperpolarization secondary to MOR activation. Sex difference has also been noticed in the MOR messenger-signaling cascade.

Sex hormones also influence spinal cord pain modulation. When estrogen levels are high, spinal antinociception was robust in female rats and was comparable to males. This is because estrogen has been found to facilitate heterodimerization of kappa-opioid receptors (KOR) and MOR (KOR/MOR heterodimers), and the KOR binding of opioids plays a significant role in the spinal antinociception in females.

Hormonal influence in peripheral pain processing has also been studied, especially in inflammatory pain. Inflammation-induced proinflammatory peptides’ release has been found to vary with the phase of the menstrual cycle.

Dimorphism in a number of other pain neurotransmitters and their receptors has also been studied. Some examples include NMDA receptors, orphanin FQ/nociception, protein kinases, toll-like receptor 4 (TLR4), adenosine receptors, cannabimimetic lipids, cytokine expression, monoamine receptors, neuregulin 1, and neurosteroids. All the above-discussed gender difference in nociceptive and pain-modulating pathways are significant, since they may also play an important role in sexual dimorphism of opioid analgesia, which is discussed later.

Comorbid conditions
Females with chronic pain conditions show increased pain facilitation such as temporal summation, and this phenomenon is not seen in males. Increased prevalence of depression and anxiety in females compared to males is also a likely cause of gender difference in pain perception.

Social factors
Social factors besides genetics and gender differences can influence pain perception significantly. Gender role expectations, stereotypes, and cultural differences in pain-related beliefs play an important role in gender difference in pain across various cultural and ethnic backgrounds. Past life pain experiences and environmental stress have also been shown to influence pain perception. Childhood abuse has been found to be associated with an increased incidence of chronic pain in adulthood.

Psychological factors
Behavioral modifications, pain coping strategies, represent the first response in handling pain. Females are known to use a variety of coping mechanisms such as seeking social support, emotion-focused techniques, attention focus, cognitive re-interpretation, and positive self-statement. Men more frequently engage in problem-focused techniques and behavioral distraction to handle pain.

Women are known to catastrophize more than men, and this involves magnification and self-rumination of pain-related information. Catastrophizing is associated with chronic and persistent pain. Men show higher degrees of self-efficacy, which refers to the belief that one can successfully perform a behavior to achieve a goal.

Incidence of depression and anxiety differ among males and females, and these psychological factors increase the risk for pain perception and transition from acute pain to chronic pain.

Gender and analgesic response
The gender differences in drug response can either be pharmacokinetic or pharmacodynamic differences. Body composition and metabolism differ between genders. Sex hormones also influence protein binding and metabolism of various drugs, introducing a pharmacokinetic dimorphism.
Examples of pharmacodynamic differences include MOR dimorphism and sex hormonal influences on MOR second messenger activation. The existence of alternate, sex-specific, pain modulating pathways also influences analgesic response.

It is observed that women are more likely to be prescribed analgesic medications especially nonsteroidal anti-inflammatory agents (NSAIDs). Women also use more over the counter analgesics compared to men. This may reflect a higher prevalence of many inflammatory and chronic pain conditions among women compared to men. Among NSAIDs, men have demonstrated better pain control with ibuprofen, while women reported better analgesia with ketorolac, but the abovementioned studies measured response to experimental pain. In an animal study, cyclooxygenase (COX) knockout female mice exhibited reduced joint destruction compared to COX knockout male mice. Thus, a gender difference in analgesic and anti-inflammatory properties of NSAIDs is possible.

Studies on gender differences in opioids have yielded mixed results. Postoperative morphine consumption has been found to be lower in women compared to men. Most of these studies examine the dose of opioid consumed, which may also be influenced by the gender-specific differences in the side effect profile of the opioid, rather than the analgesic efficacy itself. Some studies have measured the gender difference in analgesic efficacy of morphine. Some of them reported better morphine analgesia in women, some reported in men, and others reported no gender difference. There are some animal studies that report a greater degree of morphine analgesia in males. There are a number of factors contributing to the above finding.

The dimorphism of PAG-RVM pain modulation pathway has been already discussed. Morphine-induced activation of PAG-RVM neurons was significantly higher in males. Effects of sex hormones on MOR have also been discussed. Morphine, in addition to its action on MOR, has also been found to act on TLR4 of glial cells, inducing a neuroinflammatory response, which directly opposes morphine analgesia. More active innate immunity and a greater degree of TLR4 expression in females may be another reason for the gender difference in morphine analgesia.

Women are shown to experience better analgesia in response to mixed action opioids such as butorphanol, nalbuphine, and pentazocine. One significant example is the gene–sex interaction involving the melanocortin receptor (MC1R) gene. Red-haired, fair-skinned women with two allelic variants of the MC1R gene demonstrated better analgesia from pentazocine compared to red-haired men and women who did not have the allelic variants.

Females also showed an increased incidence of opioid-related adverse effects such as respiratory depression and postoperative nausea and vomiting (PONV) compared to males. Prepubertal girls have been shown to have a greater incidence of PONV and respiratory depression after tonsillectomy at higher morphine doses compared to boys. This unequal burden of adverse effects can contribute to lower opioid consumption in females.

Differences in analgesic response to antiepileptic and antidepressant medications are not widely studied. There is one study that reported no gender difference in analgesic efficacy of paroxetine. Knowledge about gender difference in response to regional analgesic modalities is also limited. From the above discussion, it becomes clear that there is no strong evidence that would support a gender-specific analgesic intervention in most clinical situations, at present.

Genetic differences in pain and analgesia
Each person is unique in the way he/she responds to pain; similarly, response to analgesic therapy also immensely varies with each individual. Race of an individual imposes an unequal burden of postoperative pain and adverse effects to analgesics. One observational study showed that Caucasian children have less postoperative pain and a higher incidence of opioid-related adverse effects after tonsillectomy. Another study reported that Asian Americans have a lower pain threshold and tolerance to experimental pain compared to non-Hispanic Whites. In a recent review of the literature on racial differences in experimental pain, it was concluded that ethnic minorities such as African Americans and Hispanics showed lower tolerance and greater unpleasantness scores for suprathreshold pain stimuli compared to non-Hispanic Whites. There was no strong evidence of a racial difference in pain threshold. The authors concluded that the difference in tolerance and pain ratings in the suprathreshold range is relevant to clinical pain experience and more research is required in exploring the biopsychosocial factors that cause this difference. These demonstrate the role of genetic variation (genetic ancestry) along with psychosocial and environmental factors and life experiences in shaping an individual’s pain experience.

The same drug at the same dosage may cause therapeutic effects in some and adverse drug effects in the others, while some others may experience no effect at all. This wide range of variability is in part due to genetic variability. The conventional analgesic regime that is based on the type of pain, its
intensity, age, and body weight of the person does not take into account this genetic variability, thus introducing a huge factor of uncertainty. Pharmacogenomics may have a big role in the dawn of the era of personalized medicine, tailored to meet the individual patient’s profile, thereby ensuring better efficacy and absolute safety.

The molecular basis of this variability includes a number of genetic variants. The most common genetic variant is the single-nucleotide polymorphism (SNP), which represents the alteration in one single base in the DNA fragments. Deletion or insertion of single or multiple base pairs, continuous repeats of 2–4 bases (variable number tandem repeats [VNTR]), repeats of longer DNA fragments (micro- and minisatellites), repeats of larger DNA fragments or the whole genes (copy number variants [CNV]), and chromosomal aberrations constitute the other genetic variants. These variants, under multiple influences, express themselves resulting in the unique phenotype. This is effected via the change in structure or function or level of expression of various proteins, including enzymes, transport proteins, receptors, and second messenger systems.

Functional pain genomics
Genetic variability in the field of pain includes functional pain genomics and pharmacogenomics. Functional pain genomics explains the individual risk of developing pain, pain intensity, intrinsic pain modulation, and individual response to pain. Some examples include genetic conditions such as congenital insensitivity to pain, channelopathy-associated insensitivity to pain, and primary erythromelalgia. There are few other single-gene pain disorders. The above conditions are very rare, but understanding the pathophysiology of the above conditions may open new targets for analgesic drug therapy and for genetic intervention in pain management. For example, black mamba venom has been found to abolish pain by its action on acid-sensing ion channels. Another clinically relevant finding is the existence of polymorphism in minor A allele of SCN9A rs6746030 gene, causing altered pain threshold, resulting in individuals to experience different amounts of pain, in response to standard nociceptive stimulus. This is important because pain intensity is usually a major factor dictating choice and dosage of analgesics.

Individual differences in pain sensitivity and perception may be partly explained by differences in nociceptive pathways. Catecholamines, such as norepinephrine and dopamine, play a vital role in these pathways, and CNS dopamine levels are related to the production of endogenous opioids that modulate pain. Genetic variability of the COMT gene, which codes for catechol-O-methyl transferase (COMT), an enzyme that degrades catecholamines in the CNS, has been found to play a role in individual pain perception. Similarly, a number of other gene polymorphisms are linked to individual pain sensitivity. These include genes coding for GTP cyclohydrolase 1 (GCH1), estrogen receptor (ESR1), MOR (OPRM1), neurotropin tyrosine kinase receptor type 1 (NTRK1), nerve growth factor β (NGFβ), and so on.

Another area involving functional genomics in pain perception is the role of psychological factors in pain experience, especially chronic pain. In a study, the presence of a certain polymorphism in the promoter region of the serotonin transporter gene 5-HTTLPR has been found to correlate with neurotic behavior, high levels of anxiety, self-doubt, and negative emotions. The abovementioned personality traits cause inability to cope with negative emotions associated with pain, resulting in catastrophizing. Similarly, serotonin (5HT) is involved in the modulation of depression. Persons with certain alleles of 5HTR1A and 5HTR2A (serotonin receptors) are found to show a higher incidence of postoperative depression and pain.

Pharmacogenomics
Pharmacogenomics is the study of genetic variabilities that underlie variations in drug response. These variations may be pharmacokinetic or pharmacodynamic differences. In general, pharmacokinetic variability is seen at two levels, either at the conversion of the prodrug to its active form or at the elimination of the active drug. Other areas of pharmacokinetic variability include protein binding of the drug and the transmembrane transport of the drug, which determine the effect site concentration of the drug. Pharmacodynamic variations occur at receptor binding, and second messenger activation, that occurs after receptor binding.

Pharmacokinetics
The metabolism of drugs occurs in two phases. Phase I involves oxidation, reduction, hydrolysis, and so on. Phase II involves conjugation of substrates to form water-soluble products. Majority of the Phase I enzymes belong to the cytochrome P 450 (CYP450) family, which is responsible for the metabolism of over 80% of all therapeutic drugs. Some of the notable subfamilies include CYP2D6 and CYP2C9.

CYP2D6 enzymes metabolize over 20% of all currently available drugs and are subject to over 100-fold genetic variability in their expression and level of activity. There are more than 100 CYP2D6 alleles identified that occur in varying frequencies in various ethnic groups.
allelic combinations and variants, patients can be categorized under the following four phenotypic groups: poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). Codeine is a widely used opioid, which undergoes CYP2D6-mediated O-demethylation to form its active drug morphine. Codeine itself is a prodrug, with lower affinity and intrinsic activity on MOR. PMs produce very low amounts of morphine, while UM produce excessive amounts of morphine. Therefore, PMs show no or subnormal therapeutic response to codeine, while UM exhibit significant adverse effects including respiratory depression, excessive sedation, and vomiting. There are many case reports of codeine-induced respiratory depression and deaths in UM, especially in children and in breast-fed neonates after maternal codeine administration.95–98 This has led to the US Food and Drug Administration’s warning response to tramadol.99,100 Respiratory depression has been mediated CNS antinociceptive pathways, the major analgesic action is via \(-\text{desmethyltramadol}\). Hence, the phenotype of CYP2D6 plays a major role in an individual’s analgesic response to tramadol.\(^9\)\(^\text{10}\) Respiratory depression has been reported in UM after tramadol administration.2

Tramadol is another CYP2D6 substrate and is transformed into its active metabolite \(O\)-desmethyltramadol. Though tramadol itself has some analgesic action via its action on MOR and nonopioid serotonin, noradrenaline-mediated CNS antinociceptive pathways, the major analgesic action is via \(O\)-desmethyltramadol. Hence, the phenotype of CYP2D6 plays a major role in an individual’s analgesic response to tramadol.\(^9\)\(^\text{10}\) Respiratory depression has been reported in UM after tramadol administration.2

Another example is genetically variable CYP3A system involved in the conversion of parecoxib to valdecoxib.80 Tricyclic antidepressants such as amitriptyline are used as co-analgesics especially in chronic pain. They undergo activation in the liver, which occurs in the following two steps: CYP2D6 hydroxylation and CYP2C19 demethylation. CYP2D6 PMs have higher blood concentrations of cyclic antidepressants, hence, an increased incidence of side effects such as arrhythmia and myelosuppression.101

Uridine diphosphate glucuronosyltransferase (UGT) belongs to a group of Phase II enzymes involved in conjugation reactions. Morphine is a substrate of UGT2B7 in the liver and is conjugated to two metabolites such as morphine 3 glucuronide (M3G) and morphine 6 glucuronide (M6G).102 M3G forms 75–85% of the metabolites and is pharmacologically inactive. M6G is the minor metabolite (5–10%) and is a potent analgesic. A number of polymorphisms of the UGT enzyme have been identified. Altered response to morphine in relation to specific UGT genotypes has been observed in various studies.103,104 Similarly, methadone, fentanyl, alfentanil, and sufentanil elimination are subject to genetic variability in the CYP3A enzyme system.105,106

NSAIDs are widely used nonopioid analgesics, alone or as part of a multimodal analgesic regimen. They are metabolized and eliminated by the CYP2C9 enzyme system, which has been known to show a wide genetic variability. PMs show decreased clearance and increased incidence of NSAID toxicity, especially gastrointestinal bleeding.107–108 CYP2C9 is also involved in warfarin metabolism, allelic variants that decrease the clearance of warfarin and increase bleeding risk, which is compounded when NSAIDs are prescribed alongside warfarin in patients carrying these variants.111

The P-glycoprotein ABCB1/MDR1 transporter is an ATP-dependent efflux transporter found in various tissues. It greatly affects the plasma and effect site concentrations of the substrate drugs. The \(ABCB1\) gene is highly polymorphic. Morphine is a P-glycoprotein substrate, which transports morphine out across the blood–brain barrier, hence decreases CSF concentration of morphine. Hence, genetic variability in \(ABCB1\) may be responsible for morphine-induced respiratory depression and the significant variability in analgesic response to morphine.112 There is also a study showing prolonged respiratory depression after fentanyl administration in certain \(ABCB1/MDR1\) genotypes.113,114

Hepatic cellular uptake of morphine is mediated through organic cation transporter (OCT1), and efflux of M3G and M6G is mediated through ABCC3. Genetic polymorphism in OCT1 has also been studied.115

Pharmacodynamics

Drugs interact with their specific receptors and initiate a cascade involving the second messenger system, finally culminating in the drug effect. The components in this cascade are subject to genetic variability resulting in variable responses.

MOR belongs to a family of 7-transmembrane G-protein-coupled receptors (GPCR). \(OPRM1\) gene coding for MOR is highly polymorphic, and there are case reports of \(OPRM1\) variants with significantly decreased analgesic response to opioids and greater postoperative opioid requirements.116,117 There are many studies on genetic variability of MOR and its relation to pain, but the results are inconsistent.118,119

Nonfunctional variants of the \(MC1R\) gene, which results in red hair and fair skin, are associated with sexual dimorphism in kappa-opioid responses. Red-haired women with these \(MC1R\) variants are known to require a lesser dose of drugs such as pentazocine compared to red-haired men.120
NSAIDs act through the inhibition of COX pathways. Prostaglandin-endoperoxide synthase (PTGS) 1 and 2 code for COX 1 and 2, respectively. Genetic variations in these enzymes can result in an altered NSAID response.121 Individuals with an increased expression of PTGS 2 and hence COX 2 experience better analgesic response to COX 2-specific agents such as celecoxib, while lower levels of expression of COX 2 result in better analgesic response to nonselective NSAIDs.84

COMT degrades neurotransmitters such as epinephrine, norepinephrine, and dopamine, which play an integral role in CNS pain pathways. Increased dopamine suppresses the production of endogenous opioid peptides, which in turn upregulates opioid receptor levels and hence altered response to opioids. Genetic variability in COMT expression has been related to variability in opioid dose requirements.122–124

Local anesthetics are sodium channel inhibitors; hence, genetic variations in sodium channels may be expected to alter local anesthetic binding and response. This has been proven by in vitro studies showing greater resistance to lidocaine in certain mutations of the SCN9A gene coding for sodium channels.125 This has also been linked to increased susceptibility to local anesthetic toxicity.126

Apart from pharmacokinetic and pharmacodynamic variabilities in drug responses, genetic variability in immune-mediated drug hypersensitivity has been studied. Antiepileptics are increasingly used in the management of chronic pain and neuropathic pain. These anticonvulsants commonly cause cutaneous adverse drug reactions including fatal ones such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).127 These reactions are HLA-mediated immune reactions, and incidence of these adverse reactions is closely linked to specific HLA alleles.128–131

Clinical application of pain genomics
The CPIC has put forth dosing guidelines based on pharmacogenetic variations for various drugs. There are dosing guidelines for codeine based on CYP2D6 genotype.132 For PMs, it is suggested to consider other opioids such as morphine, NSAIDs, and acetaminophen because of no or suboptimal analgesic response to codeine therapy. Alternative analgesics need to be considered for UMs as codeine and tramadol are expected to cause significant and life-threatening opioid adverse effects including respiratory depression and death.

Based on the CYP2C9 genotype, half the lowest recommended doses of NSAIDs have to be started for PM, in order to avoid complications such as gastrointestinal bleeding.127 Similarly, based on CYP2D6 genotype, doses of tricyclics used for chronic pain are to be reduced by 60% to avoid arrhythmias and myelosuppression in PMs.127

Knowledge on functional pain genomics and epigenetic modifications have opened new avenues for pain therapy. Epigenetics refers to the functional genetic changes, not directly involving changes in the nucleotide sequence of the gene but involving increase or decrease in the expression of gene, in response to environmental or developmental cues.94 These changes are effected by dynamic, reversible chemical modification of the genome and are involved in differential gene expression throughout life. Some examples include DNA methylation regulated by DNA methyltransferases and histone acetylation regulated by histone deacetylases (HDAC). Poorly managed acute pain is known to increase pain sensitivity and the risk of chronic pain states, and epigenetic modifications are found to play an important role in this process.94 Drugs that target enzymes responsible for epigenetic variations are under development. In an animal pain model, DNA methyltransferase inhibitor, zebularine, has been found to reduce pain sensitivity.133,134 Similar studies have been done on animal models using HDAC inhibitors as well.135 Valproic acid, an HDAC inhibitor, has been found to improve pain scores in humans with type II diabetes mellitus.136

Another potential development in the field of pain is the gene therapy, which involves the use of viral vectors, which are used to introduce a promoter sequence in the host cells, which drives the gene expression of interest. This allows a persistent expression of a protein-based endogenous analgesic agent at the site of action.94 This can significantly reduce the side effects of pharmacotherapy, but an inadequate expression of the transgene and immune elimination of the vector virus are the limitations.137 Nonviral insertion techniques are being studied to overcome these problems.137 A study has been done in cancer patients, involving the PENK gene, encoding for preproenkephalin, which is the precursor of 6-met-enkephalin and 1-leu-enkephalin, which are endogenous delta-opioid receptor ligands. The highest virus groups have reported 50% lower pain on numerical rating scale.138

Conclusion
There is a lack of robust evidence to support a gender-specific analgesic management. Intragroup variations in pain perception at various stages of sexual development and a wide range of individual variations seem to be more clinically relevant than a broader gender categorization. Clinical application of genetic knowledge in pain management is still primitive due...
to both existing knowledge gaps and the cost and access constraints. Urine drug testing is a commonly used tool for therapeutic monitoring. The qualitative tests have a high incidence of both false positives and false negatives. The quantitative assays are affected by a number of factors including the volume status and renal function of the patient. It poorly reflects the plasma drug level and the effect site concentration. The plasma drug level monitoring using mass spectrometry is a more reliable tool for therapeutic monitoring, but it does not give any idea about the pharmacodynamics of the drug. Genetic testing is still not widely adopted due to accessibility and questionable cost-effectiveness. Currently, genetic testing on oral, buccal mucosal samples has been clinically validated and also economically feasible; several SNPs are readily available for clinical use. With increasing number of studies on pain genetics and genome-wide association studies (GWAS) on pain underway, widespread genetic testing is likely to become more practical and widely accessible in the future. Personalized management algorithms for different pain models, taking into account the gender and multiple genetic variations, along with other contributing factors seem to be a reality in near future.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


100. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype

99. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Con-

98. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacoge-

96. Madadi P, Koren G. Pharmacogenetic insights into codeine anal-

95. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine,

94. Kapur BM, Lala PK, Shaw JL V. Pharmacogenetics of Chronic Pain

93. Lebe M, Hasenbring MI, Schmieder K, et al. Association of serotonin-


90. de Gregori M, Diatchenko L, Ingelmo PM, et al. Human Genetic

88. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltrans-


85. Diochot S, Baron A, Salinas M, et al. Black mamba venom pep-

83. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

79. Kim HJ, Yang GS, Greenspan JD, et al. Racial and ethnic differences

72. Packiasabapathy and Sadhasivam Pain


115. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR,

113. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic


110. Kapur BM, Lala PK, Shaw JLV. Pharmacogenetics of Chronic Pain

109. Pilotto A, Seripa D, Franceschi M, et al. Genetic Susceptibility to Non-


105. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual

104. Fujita K, Ando Y, Yamamoto W, et al. Association of UGT2B7 and


102. Fillingim RB, Atzeni F, D’Melo D, et al. OPRM1 and genetic


genealogy-based dose recommendations for antidepressants: a first


99. Matic M, Norman E, Rane A, et al. Effect of UGT2B7 -900G>A (-842G>A; rs7483135) on morphine glucuronidation in pre-

98. Fujita K, Ando Y, Yamamoto W, et al. Association of UGT2B7 and


96. Madadi P, Koren G. Pharmacogenetic insights into codeine anal-

95. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine,

94. Kapur BM, Lala PK, Shaw JL V. Pharmacogenetics of Chronic Pain

93. Lebe M, Hasenbring MI, Schmieder K, et al. Association of serotonin-


90. de Gregori M, Diatchenko L, Ingelmo PM, et al. Human Genetic

89. de Gregori M, Diatchenko L, Ingelmo PM, et al. Human Genetic

88. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltrans-


86. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine,

85. Diochot S, Baron A, Salinas M, et al. Black mamba venom pep-

84. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

83. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

82. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

81. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

80. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

79. Kim HJ, Yang GS, Greenspan JD, et al. Racial and ethnic differences

78. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syn-

77. Sadhasivam S, Kerekes EH, Chidambaran V, et al. Morphine clear-


72. Packiasabapathy and Sadhasivam Pain

71. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic require-


68. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and
CYP2C19: ethnic variation and clinical significance. Curr Clin Phar-

67. Park HJ, Shin HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic
polymorphisms in the ABCB1 gene and the effects of fentanyl in

66. Kesimci E, Engin AB, Kanbak O, Karahali B. Association between
ABCB1 gene polymorphisms and fentanyl’s adverse effects in
Turkish patients undergoing spinal anesthesia. Gene. 2012;493(2):
273–277.


